As such, LAG-3 inhibitors remain a promising novel tumor immunotherapy target beyond PD-1/PD-L1 and CTLA-4 inhibition.75, , –78 The findings of addition of relatlimab to the immunotherapy backbone in melanoma have accelerated other research studies to investigate further LAG-3-directed therapy combinations. This evidence concerns the gene CTLA4 and melanoma.